Sub-Total: $0.00 USD
Predict Drug-Induced Liver Injury Early with Human-Relevant Liver Toxicity Assays
INDIGO Biosciences provides fast, reliable in vitro hepatotoxicity screening services to help drug discovery teams identify hepatotoxic compounds before advancing them to preclinical or clinical development stages. INDIGO's hepatotoxicity assay leverages upcyte® human hepatocytes, a physiologically relevant model for predicting drug-induced liver injury (DILI).
Why Choose INDIGO’s Hepatotoxicity Services?
Human Hepatocyte Model: upcyte® Cells
Our assay uses upcyte® hepatocytes, which retain liver-specific functions such as:
- CYP450 enzyme activity
- Drug transporter expression
- Albumin production
Unlike immortalized cancer derived cell lines (e.g., HepG2), upcyte® hepatocytes are derived from healthy human liver tissue and retain more physiologically relevant functions, offering greater predictive power for assessing liver toxicity.
Quantitative and High Throughput
Our platform supports:
- 96-well high-throughput screening
- IC₅₀ determination
- Rapid comparison of analogs or compound libraries
Actionable Data for Safer Decisions
- Identify hepatotoxic liabilities during hit-to-lead or lead optimization.
- Generate IC₅₀ values and dose-response curves to inform candidate selection.
- Use as part of a tiered profiling strategy alongside receptor activation panels.
Fast Turnaround & Expert Support
- INDIGO’s scientists assist with study design and data analysis
- We can also offer follow-up assay recommendations
In Vitro Assessment of Drug-Induced Liver Injury Using Physiologically Relevant Human Hepatocytes
Drug-induced liver injury (DILI) is one of the most common causes of clinical trial failure and post-market drug withdrawal. INDIGO Biosciences offers a robust hepatotoxicity screening service built on a platform that delivers predictive insight into liver safety early in your drug discovery process.
Our hepatotoxicity service is powered by INDIGO’s Hepatotoxicity Assay, which utilizes upcyte® human hepatocytes, proliferating, primary-like hepatocytes that retain metabolic competence and liver-specific functionality. This system enables quantitative, reproducible detection of cytotoxic effects in a high-throughput in vitro format.
INDIGO's Hepatotoxicity Assay
This luciferase based viability assay uses upcyte® hepatocytes, normal human liver cells that can proliferate in culture and possess functional and inducible CYP450 enzymes to deliver highly predictive liver toxicity data. Luciferase expression depends on normal cellular processes such as energy metabolism, transcription, and translation. Any compound that disrupts these pathways reduces luciferase activity in a dose-dependent manner. As a result, changes in luminescence between treated and untreated cells serve as a sensitive indicator of cytotoxicity. Additionally, metabolism-dependent toxicity is captured as drugs are converted into more (or less) toxic forms by active CYP450 enzymes.
Get Reliable Data & Clear Reports from Our Expert Scientists
Get Reliable Data & Clear Reports from Our Expert Scientists
Full study report with IC₅₀ values and viability curves
Raw data and processed results in publication-ready format
Optional consultation to interpret results or plan follow-up testing
